Drug:
Reaction: OFF LABEL USE
20260101 - 20261231
No. 1 - 100
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 1 | 26555335 |
US |
1 | |
Off label use, Pain, |
||||
TOCILIZUMAB, |
||||
| 2 | 26555445 |
AR |
67 | 1 |
Urticaria, Pruritus, Rash, Acne pustular, Dry skin, Epistaxis, Skin fissures, Miliaria, Perioral dermatitis, Sensitive skin, Skin burning sensation, Erythema, Lip dry, Skin disorder, Off label use, |
||||
PANITUMUMAB, PANITUMUMAB, PANITUMUMAB, PANITUMUMAB, |
||||
| 3 | 26555460 |
US |
56 | 2 |
Contusion, Off label use, Diarrhoea, |
||||
ABEMACICLIB, |
||||
| 4 | 26555479 |
35 | 1 | |
Collagenous gastritis, Off label use, |
||||
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE, IRON, |
||||
| 5 | 26555487 |
US |
42 | 2 |
Off label use, Asthenia, Headache, Dizziness, Pyrexia, Swelling face, Off label use, |
||||
BOTULINUM TOXIN TYPE A, BOTULINUM TOXIN TYPE A, BOTULINUM TOXIN TYPE A, BOTULINUM TOXIN TYPE A, |
||||
| 6 | 26555491 |
US |
||
Product dose omission issue, Off label use, |
||||
LENALIDOMIDE, |
||||
| 7 | 26555497 |
US |
||
Off label use, Malaise, |
||||
LENALIDOMIDE, |
||||
| 8 | 26555509 |
US |
4 | 2 |
Intentional product use issue, Off label use, |
||||
IPRATROPIUM BROMIDE, ALBUTEROL SULFATE, ALBUTEROL, |
||||
| 9 | 26555536 |
EU |
59 | |
Lymphoma, Testicular neoplasm, Richter^s syndrome, Submandibular gland enlargement, Dysphonia, Stress, General physical health deterioration, Pain in extremity, Night sweats, Dyspnoea, Dyspnoea, Asthenia, Off label use, |
||||
RITUXIMAB, VENETOCLAX, PIRTOBRUTINIB, |
||||
| 10 | 26555539 |
61 | 1 | |
Serotonin syndrome, Drug interaction, Off label use, |
||||
SERTRALINE, |
||||
| 11 | 26555548 |
US |
55 | |
Drug ineffective, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, |
||||
| 12 | 26555562 |
EU |
||
Angioedema, Ocular hypertension, Chronic spontaneous urticaria, Condition aggravated, Urticaria, Osteoporosis, Asthenia, Myalgia, Drug intolerance, Off label use, |
||||
OMALIZUMAB, CYCLOSPORINE, |
||||
| 13 | 26555563 |
1 | ||
Middle insomnia, Terminal insomnia, Enuresis, Off label use, |
||||
SERTRALINE HYDROCHLORIDE, CLONIDINE, |
||||
| 14 | 26555567 |
US |
2 | |
Feeling abnormal, Arthropathy, Therapy interrupted, Off label use, |
||||
ETANERCEPT, ETANERCEPT, |
||||
| 15 | 26555570 |
ZA |
69 | 2 |
Off label use, Retinal thickening, |
||||
FARICIMAB, |
||||
| 16 | 26555574 |
86 | 1 | |
Dizziness, Off label use, |
||||
SERTRALINE HYDROCHLORIDE, DUPILUMAB, |
||||
| 17 | 26555578 |
US |
||
Drug ineffective, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, |
||||
| 18 | 26555579 |
US |
40 | |
Drug effect less than expected, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, |
||||
| 19 | 26555581 |
US |
||
Drug ineffective, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, |
||||
| 20 | 26555591 |
US |
||
Drug ineffective, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, |
||||
| 21 | 26555592 |
US |
||
Drug ineffective, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, |
||||
| 22 | 26555593 |
US |
||
Drug ineffective, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, |
||||
| 23 | 26555594 |
US |
||
Eyelid irritation, Eyelid ptosis, Ocular hyperaemia, Lacrimation increased, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, |
||||
| 24 | 26555611 |
EU |
48 | 2 |
Pancytopenia, Off label use, |
||||
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL HYDROCHLORIDE, PREDNISONE, |
||||
| 25 | 26555629 |
US |
||
Drug ineffective, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, |
||||
| 26 | 26555630 |
US |
40 | |
Injection site mass, Tenderness, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, |
||||
| 27 | 26555631 |
US |
||
Blepharospasm, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, |
||||
| 28 | 26555632 |
US |
||
Drug effect less than expected, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, |
||||
| 29 | 26555633 |
US |
34 | |
Drug effect less than expected, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, |
||||
| 30 | 26555634 |
US |
||
Drug effect less than expected, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, |
||||
| 31 | 26555636 |
US |
||
Drug effect less than expected, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, |
||||
| 32 | 26555637 |
US |
||
Drug effect less than expected, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, |
||||
| 33 | 26555638 |
US |
||
Drug ineffective, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, |
||||
| 34 | 26555639 |
US |
53 | |
Headache, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, |
||||
| 35 | 26555640 |
US |
||
Drug ineffective, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, |
||||
| 36 | 26555641 |
US |
||
Periorbital swelling, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, |
||||
| 37 | 26555685 |
47 | 2 | |
Ketosis, Off label use, Product dose omission issue, |
||||
TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, LEVOTHYROXINE SODIUM, DULOXETINE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE, |
||||
| 38 | 26555690 |
64 | ||
Psoriasis, Mental status changes, Depression, Stress, Drug ineffective, Off label use, |
||||
BIMEKIZUMAB, BIMEKIZUMAB, UPADACITINIB, |
||||
| 39 | 26555712 |
CA |
75 | 1 |
Dementia, Off label use, |
||||
ADALIMUMAB, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB-FKJP, |
||||
| 40 | 26555734 |
US |
||
Drug ineffective, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, |
||||
| 41 | 26555744 |
US |
48 | 2 |
Infusion site erythema, Infusion site warmth, Headache, Nausea, Fatigue, Off label use, |
||||
DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE CAPSULE, LIQUID FILLED, DIPHENHYDRAMINE HYDROCHLORIDE, |
||||
| 42 | 26555782 |
US |
60 | 1 |
Product dose omission issue, Off label use, |
||||
LENALIDOMIDE, |
||||
| 43 | 26555784 |
US |
66 | 1 |
White blood cell count decreased, Off label use, |
||||
POMALIDOMIDE, |
||||
| 44 | 26555788 |
36 | 2 | |
Off label use, Maternal exposure during pregnancy, |
||||
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE, |
||||
| 45 | 26555795 |
US |
||
Drug ineffective, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, |
||||
| 46 | 26555798 |
US |
||
Drug ineffective, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, |
||||
| 47 | 26555799 |
US |
||
Drug ineffective, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, |
||||
| 48 | 26555800 |
US |
||
Drug ineffective, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, |
||||
| 49 | 26555812 |
EU |
64 | 2 |
Haematotoxicity, Fatigue, Arthralgia, Off label use, |
||||
BEVACIZUMAB, PACLITAXEL, PACLITAXEL (AIBUMIN-BOUND), CARBOPLATIN, TRAZODONE HYDROCHLORIDE, NIRAPARIB, |
||||
| 50 | 26555818 |
US |
||
Drug ineffective, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, |
||||
| 51 | 26555824 |
US |
||
Injection site papule, Injection site pruritus, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, |
||||
| 52 | 26555825 |
US |
||
Drug ineffective, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, |
||||
| 53 | 26555843 |
US |
54 | |
Drug effect less than expected, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, |
||||
| 54 | 26555857 |
US |
40 | |
Drug ineffective, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, |
||||
| 55 | 26555858 |
US |
40 | |
Drug ineffective, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, |
||||
| 56 | 26555860 |
US |
40 | |
Drug ineffective, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, |
||||
| 57 | 26555887 |
US |
68 | |
Drug ineffective, Off label use, Headache, |
||||
PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, |
||||
| 58 | 26555892 |
US |
||
Drug ineffective, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, |
||||
| 59 | 26555893 |
US |
||
Drug ineffective, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, |
||||
| 60 | 26555894 |
US |
||
Drug ineffective, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, |
||||
| 61 | 26555895 |
US |
||
Injection site swelling, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, |
||||
| 62 | 26555896 |
US |
||
Injection site pain, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, |
||||
| 63 | 26555897 |
US |
50 | |
Asthenia, Hypoaesthesia, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, |
||||
| 64 | 26555898 |
US |
32 | |
Drug effect less than expected, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, |
||||
| 65 | 26555899 |
US |
||
Drug ineffective, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, |
||||
| 66 | 26555905 |
US |
||
Periorbital oedema, Headache, Head discomfort, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, |
||||
| 67 | 26555914 |
US |
||
Drug ineffective, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, |
||||
| 68 | 26555915 |
US |
25 | |
Drug ineffective, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, |
||||
| 69 | 26555936 |
US |
45 | |
Drug effect less than expected, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, |
||||
| 70 | 26555939 |
US |
||
Drug ineffective, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, |
||||
| 71 | 26555940 |
US |
||
Drug ineffective, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, |
||||
| 72 | 26555941 |
US |
||
Drug ineffective, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, |
||||
| 73 | 26555943 |
US |
34 | |
Drug ineffective, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, |
||||
| 74 | 26555945 |
US |
||
Drug ineffective, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, |
||||
| 75 | 26555946 |
US |
||
Drug ineffective, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, |
||||
| 76 | 26555950 |
US |
43 | |
Drug ineffective, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, |
||||
| 77 | 26555951 |
US |
45 | |
Drug ineffective, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, |
||||
| 78 | 26555952 |
US |
32 | |
Drug ineffective, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, |
||||
| 79 | 26555980 |
CA |
||
Nephrolithiasis, Drug ineffective, Hyperhidrosis, Nausea, Off label use, Product use in unapproved indication, Sedation, Nightmare, |
||||
DICLOFENAC SODIUM, ESOMEPRAZOLE MAGNESIUM, IBUPROFEN SODIUM, IBUPROFEN, IBUPROFEN TABLETS, COATED, CELECOXIB, MEPERIDINE HYDROCHLORIDE, OXYCODONE AND ACETAMINOPHEN, HYDROMORPHONE HYDROCHLORIDE, RIZATRIPTAN BENZOATE, MORPHINE SULFATE, ONDANSETRON HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE, ATENOLOL AND CHLORTHALIDONE, DULOXETINE HYDROCHLORIDE, DULOXETINE, TOPIRAMATE, ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE, ACETAMINOPHEN, VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE, ALMOTRIPTAN, ALMOTRIPTAN MALATE, ONABOTULINUMTOXINA, BOTULINUM TOXIN TYPE A, GABAPENTIN, |
||||
| 80 | 26555999 |
CA |
56 | |
Hospitalisation, Antiphospholipid syndrome, Weight decreased, Night sweats, Off label use, |
||||
INFLIXIMAB-DYYB, |
||||
| 81 | 26556010 |
62 | ||
Spinal fracture, Injection site pain, Road traffic accident, Off label use, Incorrect dose administered, Product knowledge deficit, |
||||
BIMEKIZUMAB, |
||||
| 82 | 26556033 |
EU |
44 | 1 |
Jaundice cholestatic, Liver transplant rejection, Cholangitis acute, Hepatic cirrhosis, Wound evisceration, Impaired healing, Off label use, |
||||
BEVACIZUMAB, ATEZOLIZUMAB, |
||||
| 83 | 26556046 |
US |
2 | |
Urticaria, Dyspnoea, Fatigue, Off label use, |
||||
OMALIZUMAB, OMALIZUMAB, FLUOXETINE HYDROCHLORIDE, |
||||
| 84 | 26556066 |
US |
||
Drug ineffective, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, |
||||
| 85 | 26556067 |
US |
||
Drug effect less than expected, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, |
||||
| 86 | 26556069 |
US |
||
Drug ineffective, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, |
||||
| 87 | 26556072 |
US |
||
Drug ineffective, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, |
||||
| 88 | 26556074 |
AR |
66 | 2 |
Anal incontinence, Rectal haemorrhage, Hepatitis, Skin burning sensation, Swollen tongue, Mouth swelling, Eating disorder, Pain, Rash, Pruritus, Exfoliative rash, Decreased immune responsiveness, Colostomy bag user, Acne pustular, Ill-defined disorder, Rash macular, Erythema, Blister, Malaise, Discomfort, Skin haemorrhage, Dysarthria, Drug ineffective, Dry skin, Off label use, Drug hypersensitivity, Flatulence, Blood test abnormal, Magnetic resonance imaging abnormal, Therapy interrupted, Musculoskeletal pain, |
||||
PANITUMUMAB, PANITUMUMAB, PANITUMUMAB, PANITUMUMAB, |
||||
| 89 | 26556086 |
US |
59 | 1 |
Off label use, Gout, Drug ineffective, |
||||
TIRZEPATIDE, |
||||
| 90 | 26556112 |
EU |
59 | 2 |
Subretinal fluid, Detachment of macular retinal pigment epithelium, Retinal haemorrhage, Therapeutic product effect decreased, Condition aggravated, Off label use, |
||||
RANIBIZUMAB, BEVACIZUMAB, NEBIVOLOL, NEBIVOLOL HYDROCHLORIDE, |
||||
| 91 | 26556115 |
US |
||
Drug ineffective, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, |
||||
| 92 | 26556116 |
US |
||
Drug ineffective, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, |
||||
| 93 | 26556117 |
US |
||
Drug effect less than expected, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, |
||||
| 94 | 26556118 |
US |
||
Drug effect less than expected, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, |
||||
| 95 | 26556119 |
US |
||
Muscle twitching, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, |
||||
| 96 | 26556120 |
US |
||
Drug ineffective, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, |
||||
| 97 | 26556122 |
US |
||
Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, |
||||
| 98 | 26556123 |
US |
||
Injection site vesicles, Swelling of eyelid, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, |
||||
| 99 | 26556134 |
US |
17 | 2 |
Somnolence, Off label use, Rash, Muscle spasms, Off label use, Seizure, |
||||
STIRIPENTOL, STIRIPENTOL, STIRIPENTOL, STIRIPENTOL, STIRIPENTOL, STIRIPENTOL, CLOBAZAM, CLOBAZAM, ACETAMINOPHEN, ACETAMINOPHEN 500MG, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, ACETAMINOPHEN 500MG, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ERGOCALCIFEROL, ERGOCALCIFEROL, DIAZEPAM, DIAZEPAM ORAL, DIAZEPAM ORAL SOLUTION (CONCENTRATE), DIAZEPAM, DIAZEPAM ORAL, DIAZEPAM ORAL SOLUTION (CONCENTRATE), IBUPROFEN, IBUPROFEN CAPSULES 200 MG, IBUPROFEN TABLETS USP, 200MG, IBUPROFEN TABLET, FILM COATED, IBUPROFEN ORAL, IBUPROFEN 200MG, IBUPFROFEN, IBUPROFEN TABLET, FILM-COATED, IBUPROFEN 200 MG, IBUPROFEN CAPSULE, IBUPROFEN, IBUPROFEN CAPSULES 200 MG, IBUPROFEN TABLETS USP, 200MG, IBUPROFEN TABLET, FILM COATED, IBUPROFEN ORAL, IBUPROFEN 200MG, IBUPFROFEN, IBUPROFEN TABLET, FILM-COATED, IBUPROFEN 200 MG, IBUPROFEN CAPSULE, LAMOTRIGINE, LAMOTRIGINE EXTENDED-RELEASE, LAMOTRIGINE CHEWABLE DISPERSIBLE, LAMOTIRIGINE, LAMOTRIGINE, LAMOTRIGINE EXTENDED-RELEASE, LAMOTRIGINE CHEWABLE DISPERSIBLE, LAMOTIRIGINE, MELATONIN, MELATONIN, ONDANSETRON HYDROCHLORIDE, ONDANSETRON, ONDANSETRON TABLETS, ONDANSETRON HYDROCHLORIDE, ONDANSETRON, ONDANSETRON TABLETS, POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350, SODIUM BICARBONATE, SODIUM BICARBONATE INJECTION,, SODIUM BICARBONATE, SODIUM BICARBONATE INJECTION,, |
||||
| 100 | 26556137 |
US |
||
Drug ineffective, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2026-04-28